.png)
Patent Expiries on the Horizon
- Jana Chisholm
- Apr 8
- 2 min read
For ten titans of industry in 2025, the U.S. patent runway is coming to a close. A number of biosimilars are already competing with Johnson & Johnson's Stelara, and more are expected to follow as the year progresses. The medication is the biggest loss of exclusivity in the United States since AbbVie's megablockbuster Humirea in early 2023, with $6.72 billion in sales in 2024.
Amgen's bone medications Prolia and Xgeva, Novartis' heart failure treatment Entresto, and Regeneron's eye drug Eylea are also experiencing or may experience continuous or future decreases in their key revenue sources. Last year, Amgen made $4.39 billion from its two main bone medications, Xgeva and Prolia. Its market will be eroded by generics from May. As a key combination patent approaches its expiration this summer, Novartis has issued a warning that Entresto would lose its U.S. exclusivity in summer 2025. Novartis's other top-selling drugs include Promacta and Tasigna.
Amgen is expected to release its first biosimilar of AstraZeneca's rare disease medication Soliris early in the second quarter. Additionally, Amgen’s Brilinta, a cardiometabolic medication that never lived up to expectations, may also soon lose its U.S. patent protections.The medication that seems to be the most unclear this year is Simponi/Simponi ARIA from Johnson & Johnson.Inclusion of the medication is contingent upon the possible approval and launch of Teva and Alvotech's AVT05 in the fourth quarter. Its primary patent has already expired.
See more details below:
PharmaTell Studio Hints
PharmaTell Studio includes many types of research reports, from weekly/monthly trackers to Industry and Sector Overviews. Be sure to search each catalog for topics of interest, as they may be filed under Therapeutic Areas or Industry Intel if several companies/areas are covered.
If you are a PharmaTell client and can’t access the PharmaTell-specific links, please contact us at helpdesk@pharmatell.com.
If you are not a client and would like to learn more about PharmaTell and a free trial, please email us at info@pharmatell.com, and we will be happy to assist you.
